Pluristem Therapeutics Inc. (PSTI) Expected to Announce Earnings of -$0.08 Per Share

Wall Street brokerages expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to announce ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings of ($0.08) per share during the same quarter last year. The firm is expected to announce its next quarterly earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($0.34) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.33). For the next year, analysts expect that the firm will report earnings of ($0.31) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Pluristem Therapeutics.

Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08).

PSTI has been the subject of a number of research analyst reports. Maxim Group set a $2.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 19th. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research report on Thursday, November 9th. Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. Finally, ValuEngine lowered Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $4.00.

Shares of Pluristem Therapeutics (PSTI) opened at $1.35 on Friday. Pluristem Therapeutics has a 12-month low of $1.06 and a 12-month high of $2.12. The company has a market capitalization of $149.27, a PE ratio of -4.35 and a beta of 0.19.

Institutional investors and hedge funds have recently modified their holdings of the business. Heritage Investors Management Corp bought a new stake in Pluristem Therapeutics during the 3rd quarter worth approximately $113,000. Psagot Investment House Ltd. increased its holdings in Pluristem Therapeutics by 1,705.2% during the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 122,347 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 15.0% during the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 34,742 shares in the last quarter. 4.34% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/pluristem-therapeutics-inc-psti-expected-to-announce-earnings-of-0-08-per-share.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply